NCT04227704View on ClinicalTrials.gov

Ketamine to Prevent PPD After Cesarean

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 12, 2020

Primary Completion Date

August 9, 2021

Study Completion Date

August 9, 2021

Conditions
Postpartum Depression
Interventions
DRUG

Ketamine 50 MG/ML

Administration of a 0.5 mg/kg dose of ketamine at cesarean delivery by one of two routes (subcutaneous or 40-minute IV infusion).

DRUG

Control

Administration of 0.9% Sodium Chloride (N/S)

Trial Locations (1)

63110

Washington University in St. Louis, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT04227704 - Ketamine to Prevent PPD After Cesarean | Biotech Hunter | Biotech Hunter